Derek Archila
Stock Analyst at Wells Fargo
(3.73)
# 720
Out of 4,876 analysts
179
Total ratings
46.55%
Success rate
8.38%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $53 | $44.50 | +19.10% | 8 | Jun 26, 2025 | |
| ATYR aTyr Pharma | Maintains: Overweight | $17 → $25 | $5.10 | +390.20% | 2 | Jun 20, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Equal-Weight | $143 → $129 | $128.23 | +0.60% | 9 | Jun 17, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $26 → $29 | $17.88 | +62.19% | 12 | Jun 2, 2025 | |
| SEPN Septerna | Maintains: Equal-Weight | $11 → $18 | $10.68 | +68.54% | 4 | May 16, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $26 → $19 | $7.70 | +146.75% | 6 | May 2, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $58 → $59 | $70.24 | -16.00% | 7 | Apr 30, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $25 | $11.94 | +109.38% | 5 | Apr 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $80 → $91 | $61.79 | +47.27% | 5 | Apr 7, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $6 → $3 | $1.71 | +75.95% | 10 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $4.58 | +118.34% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $1.57 | +855.41% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $723 → $741 | $562.51 | +31.73% | 11 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $43.35 | -16.96% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $23.08 | +120.97% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $6 | $1.24 | +383.87% | 4 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $12.35 | +13.36% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $4.35 | +106.90% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $16.32 | +175.74% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $1.49 | +708.08% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 | $14.71 | +83.55% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $3.60 | +566.67% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $172.93 | +67.12% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $2.42 | +354.55% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $21.14 | +75.02% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.38 | +320.17% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $1.04 | +1,823.08% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.05 | +489.85% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.86 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $28.01 | +589.04% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $81.84 | -49.90% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $15.56 | +928.28% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $9.19 | +553.24% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.84 | +499.17% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $2.17 | +2,204.15% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $13.19 | +286.66% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $26.77 | +228.73% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $23.48 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $16.83 | - | 2 | Aug 3, 2017 |
Kymera Therapeutics
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $44.50
Upside: +19.10%
aTyr Pharma
Jun 20, 2025
Maintains: Overweight
Price Target: $17 → $25
Current: $5.10
Upside: +390.20%
Blueprint Medicines
Jun 17, 2025
Downgrades: Equal-Weight
Price Target: $143 → $129
Current: $128.23
Upside: +0.60%
Apellis Pharmaceuticals
Jun 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $17.88
Upside: +62.19%
Septerna
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $10.68
Upside: +68.54%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $26 → $19
Current: $7.70
Upside: +146.75%
Incyte
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $58 → $59
Current: $70.24
Upside: -16.00%
Nurix Therapeutics
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $11.94
Upside: +109.38%
Rhythm Pharmaceuticals
Apr 7, 2025
Maintains: Overweight
Price Target: $80 → $91
Current: $61.79
Upside: +47.27%
Cabaletta Bio
Apr 1, 2025
Maintains: Equal-Weight
Price Target: $6 → $3
Current: $1.71
Upside: +75.95%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.58
Upside: +118.34%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.57
Upside: +855.41%
Feb 28, 2025
Maintains: Overweight
Price Target: $723 → $741
Current: $562.51
Upside: +31.73%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $43.35
Upside: -16.96%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $23.08
Upside: +120.97%
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $1.24
Upside: +383.87%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $12.35
Upside: +13.36%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $4.35
Upside: +106.90%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $16.32
Upside: +175.74%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $1.49
Upside: +708.08%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $14.71
Upside: +83.55%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $3.60
Upside: +566.67%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $172.93
Upside: +67.12%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $2.42
Upside: +354.55%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $21.14
Upside: +75.02%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.38
Upside: +320.17%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $1.04
Upside: +1,823.08%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $3.05
Upside: +489.85%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.86
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $28.01
Upside: +589.04%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $81.84
Upside: -49.90%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $15.56
Upside: +928.28%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $9.19
Upside: +553.24%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.84
Upside: +499.17%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $2.17
Upside: +2,204.15%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $13.19
Upside: +286.66%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $26.77
Upside: +228.73%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $23.48
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $16.83
Upside: -